EMA Withdrawn: Penbraya (Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid;Neisseria meningitidis group B fHBP protein subfamily A;Neisseria meningitidis group B fHBP protein subfamily B) — Pfizer Europe MA EEIG

View source ↗

Summary

EMA has withdrawn the marketing authorization for Penbraya, a meningococcal vaccine developed by Pfizer Europe MA EEIG. The withdrawal took effect on 14 Novembe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Disease

Drugs mentioned

• Penbraya

Snippet

Status: Withdrawn. Therapeutic area: Meningitis, Meningococcal. MAH: Pfizer Europe MA EEIG. Decision date: 14/11/2024